Showing 361 - 380 results of 78,749 for search '(( 50 ((we decrease) OR (((nn decrease) OR (a decrease)))) ) OR ( 10 we decrease ))', query time: 0.68s Refine Results
  1. 361
  2. 362

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  3. 363

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  4. 364

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  5. 365

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
  6. 366

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
  7. 367
  8. 368
  9. 369
  10. 370
  11. 371
  12. 372

    Sensitivity analysis of 50:50 model. by Rachael Miller Neilan (10678614)

    Published 2021
    “…<p>A sensitivity analysis was conducted on the 50:50 model with constant 120 pA current to determine the sensitivity of pain output to select model parameters before injury (t = 10), during injury (t = 105), and after injury (t = 240). …”
  13. 373
  14. 374

    Methodology. by Scott John (228011)

    Published 2024
    “…Upon binding of lactate YFP and CFP move farther apart, the intensity of YFP fluorescence decreases while that of CFP increases. This leads to a decrease in the YFP/CFP FRET ratio. …”
  15. 375
  16. 376

    Expanding Three-Coordinate Gold(I) Anticancer Agent Chemical Space by Charles E. Greif (21728091)

    Published 2025
    “…We report the synthesis and characterization of 14 complexes of the type (Au(R)[N̂N])<sup>+</sup>, where R = tunable biaryldialkyl phosphine ligands and [N̂N] = bidentate phenanthroline derivatives as anticancer agents. …”
  17. 377

    The decreasing rates of V<sub>p</sub> with temperature. by Nazlı Tunar Özcan (14833635)

    Published 2023
    “…The V<sub>p</sub> and the σ<sub>t</sub> of Çankırı rock salt decrease with increasing temperatures of samples whereas the σ<sub>c</sub> increases. …”
  18. 378

    Flow chart. by Raphaele Houlbracq (20558509)

    Published 2025
    “…However, subgroup analyses revealed a significant rise in OASI among nulliparous women giving birth by spatula (Group 2b), and a clinically relevant but statistically nonsignificant rise among nulliparous women delivering by forceps (Group 2a), while the prevalence of episiotomy significantly decreased. …”
  19. 379
  20. 380